Medicure Inc. (OTCMKTS:MCUJF – Get Free Report) was the target of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 3,348 shares, a drop of 93.1% from the September 30th total of 48,345 shares. Based on an average daily volume of 26,042 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are sold short.
Medicure Stock Performance
Shares of Medicure stock opened at $3.16 on Tuesday. The business has a 50-day simple moving average of $1.97 and a 200 day simple moving average of $1.11. Medicure has a one year low of $0.67 and a one year high of $3.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.97 and a quick ratio of 0.64. The firm has a market capitalization of $32.99 million, a price-to-earnings ratio of -6.20 and a beta of 1.13.
Medicure (OTCMKTS:MCUJF – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). Medicure had a negative net margin of 23.14% and a negative return on equity of 54.55%. The business had revenue of $5.36 million during the quarter, compared to the consensus estimate of $2.45 million.
About Medicure
Medicure Inc is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations.
Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome.
Further Reading
- Five stocks we like better than Medicure
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
